Cromos Pharma commences a pivotal multicountry clinical trial of OT-101 in patients with advanced pancreatic cancer
Cromos Pharma is thrilled to announce the commencement of a pivotal trial, focused on the investigation of OT-101, a collaborative effort between Oncotelic Therapeutics and Sapu Bioscience, in individuals suffering from advanced and unresectable or metastatic pancreatic cancer. With this ambitious multicountry endeavor, Cromos Pharma’s aspiration is to deliver a long-awaited enhancement in survival outcomes for patients afflicted by this devastating illness.
Please read a press release here
If you have any questions or want to find out more about how Cromos Pharma can support your next clinical trial, please contact us by emailing email@example.com.